Amgen reports pair of positive clinical trial results
Amgen announced positive results from clinical trials of two separate drugs in late August. On Aug. 30, the Thousand Oaks-based biotech giant said its Phase 3 trail evaluating daily oral doses of Lumakras, a treatment for non-small cell lung cancer, “met its primary endpoint of progression-free survival” and demonstrated statistically significant superiority over the current Read More →
Our View: Don’t forget local interests in the Diablo Canyon extension
At a State Senate committee hearing in Sacramento in late August, Gov. Gavin Newsom’s staff gave its biggest endorsement yet to a plan to extend the life of the Diablo Canyon nuclear plant in San Luis Obispo County. In the early morning hours of Sept. 1, the California Legislature passed a bill, which Newsom seems Read More →
Introducing the 40 Under 40, Class of 2022
The Pacific Coast Business Times has published its annual 40 Under 40 special report and will hold an event to celebrate the Class of 2022 on Sept. 22 at 5 p.m. at Topa Topa Brewing Company’s Colt Street location in Ventura. The 40 Under 40 published Aug. 26 and is available here on the Business Read More →
Our View: Diablo Canyon debate could give anyone whiplash
If the debate over the closing of the Diablo Canyon nuclear plant comes down to litigation, we’d support any claim by any municipality that alleged a traumatic injury from political whiplash. It certainly is true that the revival of Diablo Canyon from certain closure to the likely probability that its license will be extended beyond Read More →
Opinion: Oxnard should shy away from risky pension obligation bonds
By David Grau Inheriting a predecessor’s underfunded public pension debts is never fun, but the need to address them is unavoidable. The question before the Oxnard City Council was how — and there is both a right way and the lazy way. The right way is to adopt policies that keep the pension debt from Read More →









